{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(8)"],"submitter":["Tsavachidou-Fenner D"],"funding":["Mary K. Chapman Fund for Renal Cell Carcinoma Molecular Research, The Mary K. Chapman Foundation"],"pubmed_abstract":["<h4>Background</h4>Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated.<h4>Patients and methods</h4>Nephrectomy material from 37 patients with mRCC receiving bevacizumab +/- erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were used to carry out gene expression microarray-based profiling. Normalized protein and gene expression data were correlated with overall survival (OS) and progression-free survival (PFS) using univariate Cox hazard model and linear regression. Immunoblotting was carried out to validate the re"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pagination":["1599-1606"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4092253"],"repository":["biostudies-literature"],"pubmed_title":["Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma."],"pmcid":["PMC4092253"],"pubmed_authors":["Tsavachidou-Fenner D","Petillo D","Jonasch E","Teh B","Tannir N","Tamboli P","Mills GB","Liu W"],"additional_accession":[]},"is_claimable":false,"name":"Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma.","description":"<h4>Background</h4>Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated.<h4>Patients and methods</h4>Nephrectomy material from 37 patients with mRCC receiving bevacizumab +/- erlotinib was used for protein and gene expression assessment. Protein lysates were subjected to reverse-phase protein array profiling. RNA extracts were used to carry out gene expression microarray-based profiling. Normalized protein and gene expression data were correlated with overall survival (OS) and progression-free survival (PFS) using univariate Cox hazard model and linear regression. Immunoblotting was carried out to validate the re","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Aug","modification":"2025-04-26T09:08:48.527Z","creation":"2019-03-27T01:31:53Z"},"accession":"S-EPMC4092253","cross_references":{"pubmed":["20089566"],"doi":["10.1093/annonc/mdp600"]}}